Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ascent Therapeutics: There's Still Money in Discovery Platforms

This article was originally published in Start Up

Executive Summary

It's a common perception that venture investors have turned their backs-or at least hidden their pocketbooks-from big think platform-based biotechs in search of early stage funding. But a quick look at the large A rounds raised in recent years suggests that sentiment isn't exactly true. Start-ups with promising technologies capable of generating multiple products across a wide swath of therapeutic areas are still gaining funding despite the dearth of capital. One example: Ascent Therapeutics.

You may also be interested in...



Anchor, Ortho-McNeil-Janssen to Collaborate on Peptide Drugs

The J&J subsidiary will pay an undisclosed amount to license drugs on fewer than 10 targets in cancer and metabolic disorders.

Anchor, Ortho-McNeil-Janssen to Collaborate on Peptide Drugs

The J&J subsidiary will pay an undisclosed amount to license drugs on fewer than 10 targets in cancer and metabolic disorders.

Anchor Therapeutics' $10 Million Series B Fund May Grow Based On Near-Term Milestones

The platform company, which targets difficult to drug GPCRs, hopes to announce a Big Pharma collaboration soon, as well as project milestones that prove its worth.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel